Science Advances,
Journal Year:
2023,
Volume and Issue:
9(7)
Published: Feb. 15, 2023
T
cell
engineering
has
changed
the
landscape
of
cancer
immunotherapy.
Chimeric
antigen
receptor
cells
have
demonstrated
a
remarkable
efficacy
in
treatment
B
malignancies
hematology.
However,
their
clinical
impact
on
solid
tumors
been
modest
so
far.
expressing
an
engineered
(TCR-T
cells)
represent
promising
therapeutic
alternative.
The
target
repertoire
is
not
limited
to
membrane
proteins,
and
intrinsic
features
TCRs
such
as
high
sensitivity
near-to-physiological
signaling
may
improve
tumor
detection
killing
while
improving
persistence.
In
this
review,
we
present
results
obtained
with
TCR-T
targeting
different
families.
We
detail
methods
that
developed
identify
optimize
TCR
candidate.
also
discuss
challenges
therapies,
including
toxicity
assessment
resistance
mechanisms.
Last,
share
some
perspectives
highlight
future
directions
field.
Cancer Cell,
Journal Year:
2018,
Volume and Issue:
33(5), P. 843 - 852.e4
Published: April 12, 2018
Combination
immune
checkpoint
blockade
has
demonstrated
promising
benefit
in
lung
cancer,
but
predictors
of
response
to
combination
therapy
are
unknown.
Using
whole-exome
sequencing
examine
non-small-cell
cancer
(NSCLC)
treated
with
PD-1
plus
CTLA-4
blockade,
we
found
that
high
tumor
mutation
burden
(TMB)
predicted
improved
objective
response,
durable
benefit,
and
progression-free
survival.
TMB
was
independent
PD-L1
expression
the
strongest
feature
associated
efficacy
multivariable
analysis.
The
low
rate
NSCLCs
demonstrates
immunotherapy
does
not
overcome
negative
predictive
impact
TMB.
This
study
association
between
NSCLC.
should
be
incorporated
future
trials
examining
PD-(L)1
Science,
Journal Year:
2017,
Volume and Issue:
358(6359), P. 58 - 63
Published: Oct. 5, 2017
The
immune
system
varies
in
cell
types,
states,
and
locations.
complex
networks,
interactions,
responses
of
cells
produce
diverse
cellular
ecosystems
composed
multiple
accompanied
by
genetic
diversity
antigen
receptors.
Within
this
ecosystem,
innate
adaptive
maintain
protect
tissue
function,
integrity,
homeostasis
upon
changes
functional
demands
insults.
Characterizing
inherent
complexity
requires
studies
at
single-cell
resolution.
Recent
advances
such
as
massively
parallel
RNA
sequencing
sophisticated
computational
methods
are
catalyzing
a
revolution
our
understanding
immunology.
Here
we
provide
an
overview
the
state
genomics
outlook
on
use
techniques
to
decipher
components
immunity.
Nucleic Acids Research,
Journal Year:
2017,
Volume and Issue:
46(D1), P. D419 - D427
Published: Aug. 18, 2017
The
ability
to
decode
antigen
specificities
encapsulated
in
the
sequences
of
rearranged
T-cell
receptor
(TCR)
genes
is
critical
for
our
understanding
adaptive
immune
system
and
promises
significant
advances
field
translational
medicine.
Recent
developments
high-throughput
sequencing
methods
(immune
repertoire
technology,
or
RepSeq)
single-cell
RNA
technology
have
allowed
us
obtain
huge
numbers
TCR
from
donor
samples
link
them
phenotypes.
However,
annotate
these
still
lags
behind,
owing
enormous
diversity
scarcity
available
data
on
specificities.
In
this
paper,
we
present
VDJdb,
a
database
that
stores
aggregates
results
published
specificity
assays
provides
universal
platform
couples
with
sequences.
We
demonstrate
VDJdb
versatile
instrument
annotation
data,
enabling
concatenated
view
antigen-specific
sequence
motifs.
can
be
accessed
at
https://vdjdb.cdr3.net
https://github.com/antigenomics/vdjdb-db.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Jan. 6, 2023
Abstract
Recent
advances
in
neoantigen
research
have
accelerated
the
development
and
regulatory
approval
of
tumor
immunotherapies,
including
cancer
vaccines,
adoptive
cell
therapy
antibody-based
therapies,
especially
for
solid
tumors.
Neoantigens
are
newly
formed
antigens
generated
by
cells
as
a
result
various
tumor-specific
alterations,
such
genomic
mutation,
dysregulated
RNA
splicing,
disordered
post-translational
modification,
integrated
viral
open
reading
frames.
recognized
non-self
trigger
an
immune
response
that
is
not
subject
to
central
peripheral
tolerance.
The
quick
identification
prediction
neoantigens
been
made
possible
advanced
next-generation
sequencing
bioinformatic
technologies.
Compared
tumor-associated
antigens,
highly
immunogenic
provide
emerging
targets
personalized
serve
prospective
predictors
survival
prognosis
checkpoint
blockade
responses.
therapies
will
be
aided
understanding
mechanism
underlying
neoantigen-induced
anti-tumor
streamlining
process
neoantigen-based
immunotherapies.
This
review
provides
overview
on
characterization
outlines
clinical
applications
immunotherapeutic
strategies
based
neoantigens.
We
also
explore
their
current
status,
inherent
challenges,
translation
potential.
